Enterprise Value
5.605M
Cash
3.683M
Avg Qtr Burn
-6.249M
Short % of Float
8.22%
Insider Ownership
28.01%
Institutional Own.
5.83%
Qtr Updated
01/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TAVO™-EP + OPDIVO® (nivolumab) Details Melanoma, Cancer | Phase 2 Data readout | |
TAVO™-EP + pembrolizumab Details Melanoma, Non-small cell lung carcinoma, Thermal burns, Rhabdomyosarcoma, Cancer | Phase 2 Initiation | |
CORVax12 (TAVO + SARS-CoV-2 spike glycoprotein) Details COVID-19, Hepatitis B vaccine, Hepatitis B | Failed Discontinued | |
TAVO™-EP + epacadostat + pembrolizumab Details Cancer, Head and neck cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
TAVO™-EP + pembrolizumab Details Breast cancer, Triple-negative breast cancer | Failed Discontinued |